https://www.selleckchem.com/products/bgb-15025.html Alamar Blue assay was utilized to assess cell viability. Hemocompatibility was evaluated, and samples were processed for immunohistochemistry (TNFα and IL-10). Hemocompatibility was quantified using Terminal Complement Complex (TCC) and Neutrophil elastase (NE) as an indicator. The results of the H&E staining revealed less formation of extracellular ice crystals and intracellular vacuoles in the IFC + T group compared with all other groups. The CFC group's cell viability showed better viability than the IFC group, but the highest viability was exhibited in the IFC + T group (70.96 ± 2.53, P less then 0.0001, n = 6). In immunohistochemistry, TNFα levels were lowest in both IFC and IFC + T group, and IL-10 expression had significantly reduced in IFC and IFC + T group. The results suggested that the nanoparticle encapsulated trehalose did not show significant hemocompatibility issues on the cryopreserved heart valves.The December issue of Breathe focuses on systemic diseases involving the lung read the introductory editorial by Chief Editor @ClaudiaCDobler https//bit.ly/2JtC6NG.A pro/con debate in this issue of Breathe outlines the evidence on utility and safety of bronchoscopy in patients with haematological malignancy, with concurrence that the microbiological yield is best when performed within 24 h https//bit.ly/35MKy1Y.Pulmonary rehabilitation has evolved from an "art" to "science" over the past decades thanks to the contributions of Prof Casaburi. His priorities for the future are 1) access, 2) access, and 3) access! https//bit.ly/3j2aSdr.Up to 60% of patients with haematological malignancy will develop pulmonary infiltrates at some point in their disease course. Bronchoscopy should be used early in patients without respiratory failure as diagnostic yield is highest in the first 1-2 days of illness. Perceptions that patients with haematological malignancy are at higher risk of complications from bronchoscopy has